about
The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasisDissecting the essentiality of the bifunctional trypanothione synthetase-amidase in Trypanosoma brucei using chemical and genetic methodsChemical validation of trypanothione synthetase: a potential drug target for human trypanosomiasisTrypanothione-dependent glyoxalase I in Trypanosoma cruziNitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospectsChemical, genetic and structural assessment of pyridoxal kinase as a drug target in the African trypanosomeAllosteric activation of trypanosomatid deoxyhypusine synthase by a catalytically dead paralogDual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovaniActivation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in LeishmaniaThe R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis.Identification of Chlamydia trachomatis genomic sequences recognized by chlamydial divalent cation-dependent regulator A (DcrA).Visceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian subcontinent?Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.Leishmania major elongation factor 1B complex has trypanothione S-transferase and peroxidase activity.Mapping the functional synthetase domain of trypanothione synthetase from Leishmania major.TrypanoCyc: a community-led biochemical pathways database for Trypanosoma bruceiHomoserine and quorum-sensing acyl homoserine lactones as alternative sources of threonine: a potential role for homoserine kinase in insect-stage Trypanosoma brucei.Quinol derivatives as potential trypanocidal agentsIncreased levels of thiols protect antimony unresponsive Leishmania donovani field isolates against reactive oxygen species generated by trivalent antimonyPentacyclic nitrofurans that rapidly kill nifurtimox-resistant trypanosomesThe anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasisChronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis.Methylglyoxal metabolism in trypanosomes and leishmania.Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei.Biochemical and genetic characterization of Trypanosoma cruzi N-myristoyltransferase.Norspermidine is not a self-produced trigger for biofilm disassembly.Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay.Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need.Trypanosoma brucei (UMP synthase null mutants) are avirulent in mice, but recover virulence upon prolonged culture in vitro while retaining pyrimidine auxotrophy.Snapshot Profiling of the Antileishmanial Potency of Lead Compounds and Drug Candidates against Intracellular Leishmania donovani Amastigotes, with a Focus on Human-Derived Host Cells.Assessing the essentiality of Leishmania donovani nitroreductase and its role in nitro drug activation.Comparative proteomics profiling of a gentamicin-attenuated Leishmania infantum cell line identifies key changes in parasite thiol-redox metabolism.Roles of trypanothione S-transferase and tryparedoxin peroxidase in resistance to antimonialsDifferential toxicity of antimonial compounds and their effects on glutathione homeostasis in a human leukaemia monocyte cell line.Antitumor quinol PMX464 is a cytocidal anti-trypanosomal inhibitor targeting trypanothione metabolism.Chemical and genetic validation of dihydrofolate reductase-thymidylate synthase as a drug target in African trypanosomes.Dissecting the metabolic roles of pteridine reductase 1 in Trypanosoma brucei and Leishmania major.Elevated levels of tryparedoxin peroxidase in antimony unresponsive Leishmania donovani field isolates.A comparative study of methylglyoxal metabolism in trypanosomatids.ATP-dependent ligases in trypanothione biosynthesis--kinetics of catalysis and inhibition by phosphinic acid pseudopeptides.
P50
Q24633734-93903E47-2884-47D3-8B76-5F846341B80CQ24649110-C2830D20-3A15-4843-B42B-63E66375B118Q24657204-3B250885-EFCF-4CF0-939D-4C1F49B95B61Q24682276-83825C4C-BA8A-438F-BDEF-4C99778AF634Q26863285-745DF343-2C53-43EF-86B5-427E125B1371Q27671077-B5F83FEA-2B59-4B31-A2AF-77563B4FFB69Q28119052-356919DC-EF92-41E2-8482-98436459680BQ28271918-6B2295FE-0D84-46D8-91AA-4C90D77D58CEQ28553178-701D5B67-A998-4819-899C-3A4E7C0CBD21Q30447200-E0C2AEA5-0A8E-4A97-A616-D01E74FEF3C7Q33699479-41041DD5-54C6-4281-8F8C-E90FCB00E1D0Q34043521-27CB1182-F5AD-4444-BC0C-E2B9840EF7C9Q34113517-6A37AC53-3A11-4BA9-BDA6-A5DA432216BEQ34342417-F7A595D7-8239-4114-9519-CC9FFF2E11A2Q34536654-2BBDBC6D-E0FA-495B-A52B-232AA4D69F19Q35254789-E7234CFC-E4CB-435A-98FE-9942225C43FDQ35700331-B11D0B98-7E76-4879-AC9B-9FBBA91F78B1Q35761636-6D321D04-15CA-40DF-85B5-85E2CDBFED9AQ36133198-180870B3-CC6E-4784-9857-D7F4CE69B821Q36684151-C3A3EC6F-3683-47F8-A531-8D3A30E359C2Q36932080-11FC14F9-261F-49E4-B065-E6A7BD9A867FQ37377483-F0EF80B6-4FCC-46B0-8733-85F0478058D0Q37839329-5613CE65-A31A-4E85-A53A-3A6AC9146C47Q38270529-7F3B786F-CD37-4BDB-9330-E51230C1B23FQ38552084-61780E6F-8B08-4F62-8F3D-E91442EF557AQ38552121-0A35D11C-48D0-4836-94B5-9B6B52520733Q38966911-949C2BDF-C633-4BB4-9173-D15BFF2461E5Q39003990-5F865ED3-D486-43DF-B646-492A2E3A2DC3Q39104459-F8DE048A-7A83-484C-9229-967D07CAC160Q39144812-53C07C86-BC06-4293-B5F5-08A4CB75C757Q39233120-01F776E1-EFB1-456B-BE43-6EFE5D76BCA7Q39431075-7779F120-F24E-4944-80FC-7C80162B0989Q40016515-ECFFB8B4-1AA7-4A4B-916A-8602ABBFD5B4Q40345807-DF8AAAC2-ACCE-4A39-A9DB-A6A019923AABQ41781992-79B4F99E-9127-4C8D-A3DB-78F5A1F16111Q41835113-03DDBAD4-A3B6-497E-A4C9-FDEF0A55B6EAQ41908167-09ECA5BD-154E-444F-BE6E-749B5BC374C6Q42321448-0C5F60F7-42AD-4127-AE0C-19DAD8282B52Q43105426-41C8C126-C031-499A-AFB5-0AFB9AA73828Q43106044-463E9640-988E-408F-9684-C1482E72FEEE
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Susan Wyllie
@ast
Susan Wyllie
@en
Susan Wyllie
@es
Susan Wyllie
@nl
type
label
Susan Wyllie
@ast
Susan Wyllie
@en
Susan Wyllie
@es
Susan Wyllie
@nl
prefLabel
Susan Wyllie
@ast
Susan Wyllie
@en
Susan Wyllie
@es
Susan Wyllie
@nl
P106
P1153
56284550100
P21
P31
P496
0000-0001-8810-5605